Philip Stella
Overview
Explore the profile of Philip Stella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim E, Velcheti V, Mekhail T, Yun C, Shagan S, Hu S, et al.
Nat Med
. 2022 Apr;
28(5):939-945.
PMID: 35422531
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted...
2.
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk J, et al.
Oncologist
. 2019 Jun;
24(9):1149-e807.
PMID: 31152080
Lessons Learned: The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate...
3.
Patt D, Stella P, Bosserman L
J Oncol Pract
. 2018 Sep;
14(10):577-579.
PMID: 30207855
No abstract available.
4.
Lubner S, Feng Y, Mulcahy M, ODwyer P, Giang G, Hinshaw J, et al.
Oncologist
. 2018 Jun;
23(9):1006-e104.
PMID: 29853660
Lessons Learned: Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can...
5.
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang D, Kim G, et al.
BMC Cancer
. 2017 Feb;
17(1):137.
PMID: 28202004
Background: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable...
6.
Kim T, Yoon H, Stella P, Nagrath S
Biomicrofluidics
. 2015 Jan;
8(6):064117.
PMID: 25553193
Inertial microfluidics is an emerging class of technologies developed to separate circulating tumor cells (CTCs). However, defining design parameters and flow conditions for optimal operation remains nondeterministic due to incomplete...
7.
Feinberg B, Lang J, Grzegorczyk J, Stark D, Rybarczyk T, Leyden T, et al.
J Oncol Pract
. 2012 Sep;
8(3 Suppl):e38s-43s.
PMID: 22942833
Despite rising medical costs within the US health care system, quality and outcomes are not improving. Without significant policy reform, the cost-quality imbalance will reach unsustainable proportions in the foreseeable...
8.
Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al.
J Clin Oncol
. 2008 Dec;
27(5):672-80.
PMID: 19114685
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy...
9.
Demark-Wahnefried W, Polascik T, George S, Switzer B, Madden J, Ruffin 4th M, et al.
Cancer Epidemiol Biomarkers Prev
. 2008 Dec;
17(12):3577-87.
PMID: 19064574
Background: Prostate cancer affects one of six men during their lifetime. Dietary factors are postulated to influence the development and progression of prostate cancer. Low-fat diets and flaxseed supplementation may...
10.
Ansell S, Geyer S, Maurer M, Kurtin P, Micallef I, Stella P, et al.
Clin Cancer Res
. 2006 Oct;
12(20 Pt 1):6056-63.
PMID: 17062681
Purpose: Rituximab is a chimeric antibody that induces B-cell apoptosis and recruits immune effector cells to mediate cell lysis. Interleukin-12 (IL-12) facilitates cytolytic responses by T cells and natural killer...